Hybridon presents preclinical results with MDM2 antisense compound at AACR April 10, 2000 No Comments
Nonsecosteroidal, nonhypercalcemic VDR agonist with antitumor activity designed at Ligand April 7, 2000 No Comments
NewBiotics completes private placement and prepares to advance study of lead product April 7, 2000 No Comments
Novel tumor-targeting approach taken by McGill scientists using chimeric molecules April 7, 2000 No Comments
Biological effects of SU-9516, a cdk inhibitor, studied in human colon cancer cells April 7, 2000 No Comments
Updated results from G-3139 clinical trial demonstrate durable response and survival April 7, 2000 No Comments